Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 804 results for "dyspnea"

Case 38-2014 — An 87-Year-Old Man with Sore Throat, Hoarsene...

New England Journal of Medicine, 1 week ago

18 images for dyspnea

MDLinx, 2 days ago
MDLinx, 2 days ago
MDLinx, 2 days ago
MDLinx, 2 days ago
MDLinx, 2 days ago
MDLinx, 2 days ago
MDLinx, 2 days ago
MDLinx, 2 days ago
MDLinx, 2 days ago
MDLinx, 2 days ago

Dyspnea Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014

Summary 'Dyspnea- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014', report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to ...
 Individual.com1 week ago

12/21/14 - Incyte: U.S. Food and Drug Administration Approves Jakafi for Uncontrolled Polycythemia Vera [Professional Services Close - Up]

Incyte Corp. recently reported that the U.S. Food and Drug Administration has approved Jakafi (ruxolitinib) for the treatment of patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea. In a ...
 Pharmacy Choice17 hours ago Incyte: U.S. Food and Drug Administration Approves Jakafi for Uncontrolled Polycythemia Vera  Insurance News Net1 week ago 12/9/14 - Incyte: U.S. Food and Drug Administration Approves Jakafi for Uncontrolled Polycythemia Vera [Health & Beauty Close - Up]  Pharmacy Choice1 week ago

Celgene Receives Positive CHMP Opinion to Extend REVLIMID® (Lenalidomide) for Continuous Use in Patients with Newly Diagnosed Multiple Myeloma and Ineligible for Transplant

Celgene International Sàrl, a wholly owned subsidiary of Celgene Corporation ( NASDAQ: CELG ), today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a ...
 SearchBug2 days ago Celgene Receives Positive CHMP ...  World Connector Net18 hours ago CELGENE : Receives Positive CHMP Opinion to Extend REVLIMID® (Lenalidomide) for Continuous Use in Patients with Newly Diagnosed Multiple Myeloma and Ineligible for Transplant  4 Traders2 days ago
[x]  

Ghrelin-receptor agonists may be beneficial in cancer anorexia-cachexia syndrome

1. Patients with cancer anorexia-cachexia syndrome who received anamorelin gained significantly more lean muscle mass compared to the placebo group. 2. Severe adverse events related to the anamorelin treatment group were relatively rare and included ...
 2 Minute Medicine23 hours ago

CMS Proposes Posting Overall Star Rating for HHAs on Home Health Compare Website in 2015

On December 11, 2014, CMS issued a fact sheet detailing its proposal for assigning an overall star rating for each home health agency (HHA) on the Home Health Compare website starting in 2015. An HHA's star rating would be based on its performance ...
 JD Supra2 days ago HHAs to see stars on Home Health Compare  HCPro6 days ago
Yahoo! Finance

EPRS: Epirus Biopharma: An Intriguing Global Biosimilar Play

By Jason Napodano, CFA & David Bautz, PhD NASDAQ:EPRS Epirus Biopharmaceuticals ( EPRS ) is a biopharma company focused on developing, manufacturing, and commercializing biosimilar therapeutics in various jurisdictions worldwide. The company ...
 Yahoo! Finance2 days ago

Pfizer (PFE) Shows Off Significant Data From Pregabalin CR Phase 3 12/18/2014

NEW YORK--( BUSINESS WIRE )--Pfizer Inc. (NYSE:PFE) announced today top-line results from a double-blind Phase 3 study evaluating pregabalin controlled-release (CR) formulation in adult patients with postherpetic neuralgia (pain ...
 ClinicSpace3 days ago Pfizer Reports Top-Line Results From a Phase 3 Study Evaluating Pregabalin Controlled-Release Formulation as a Treatment for Patients With Postherpetic Neuralgia  CEOWorld Magazine3 days ago Pfizer : Reports Top-Line Results From a Phase 3 Study Evaluating Pregabalin Controlled-Release Formulation as a Treatment for Patients With Postherpetic Neuralgia  4 Traders3 days ago
[x]  
Advance For NPs And PAs

Another Use for Stem Cells?

Section Sponsored by: Cardiomyopathy is a common disease of the heart muscle that often leads to heart failure. 1 Nearly 500,000 patients are diagnosed with heart failure every year. 2 Current standard treatment options for cardiomyopathy ...
 Advance For NPs And PAs3 days ago
ClinicSpace

Lilly's CYRAMZA® (ramucirumab) Receives Third FDA Approval

CYRAMZA is the first treatment approved in the U.S. for use in combination with docetaxel in second-line metastatic non-small cell lung cancer INDIANAPOLIS, Dec. 16, 2014 /PRNewswire/ --Eli Lilly and Company(NYSE: LLY) has received its third U.S.
 Financial Content5 days ago Eli Lilly (LLY)'s CYRAMZA (ramucirumab) Receives Third FDA Approval 12/18/2014  ClinicSpace3 days ago Lilly's CYRAMZA (ramucirumab) Receives Third FDA Approval  Pharmacy Choice5 days ago Lilly's CYRAMZA?? (ramucirumab) Receives Third FDA Approval  Review Seeker5 days ago
[x]  
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less